Rajan Sharma
Stock Analyst at Goldman Sachs
(3.67)
# 2,129
Out of 5,108 analysts
178
Total ratings
53.1%
Success rate
5.6%
Average return
Main Sectors:
Stocks Rated by Rajan Sharma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,526p → 17,580p | 13,490p | +30.32% | 45 | Nov 3, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 1,860p → 1,850p | 1,832p | +1.01% | 33 | Nov 2, 2026 | |
| GMAB Genmab | Reiterated: Buy | $361 → $62 | $52.74 | +17.56% | 6 | Oct 29, 2026 | |
| IMCR Immunocore Holdings | Reiterated: Buy | n/a | $28.40 | - | 14 | Oct 28, 2026 | |
| EPA: ABVX ABIVAX Société Anonyme | Reiterated: Buy | €132.00 → €131.00 | €74.80 | +75.13% | 2 | Oct 13, 2026 | |
| BIT: PHIL Philogen S.p.A. | Reiterated: Hold | €18.00 → €21.00 | €20.95 | +0.24% | 9 | Oct 2, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiated Coverage: Buy | $155 | $84.18 | +84.14% | 1 | Sep 9, 2026 | |
| IMTX Immatics | Reiterated: Buy | $12 → $12 | $6.18 | +90.94% | 5 | Aug 18, 2026 | |
| AUTL Autolus Therapeutics | Rated: Buy | $5.7 → $5.8 | $1.26 | +360.32% | 6 | Aug 11, 2026 | |
| VALN Valneva SE | Downgraded: Sell | $7.5 → $4.9 | $5.64 | -13.12% | 5 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $7.25 → $5.81 | $9.80 | -40.71% | 3 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Sell | €1.30 → €1.01 | €1.72 | -41.11% | 5 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $813 → $910 | $894.77 | +1.70% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.7884 | - | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.24 | - | 5 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $45 | $88.34 | n/a | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €2.85 → €3.30 | €2.47 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $122.96 | n/a | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 2.00 | CHF 4.04 | n/a | 8 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $130.34 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $47 | $50.41 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $36.62 | n/a | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €90.00 → €100.00 | €154.80 | n/a | 6 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €44.00 | €53.00 | n/a | 7 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $20 | $14.20 | n/a | 2 | May 4, 2022 |
AstraZeneca PLC
Nov 3, 2026
Reiterated: Buy
Price Target: 16,526p → 17,580p
Current: 13,490p
Upside: +30.32%
GSK plc
Nov 2, 2026
Reiterated: Hold
Price Target: 1,860p → 1,850p
Current: 1,832p
Upside: +1.01%
Genmab
Oct 29, 2026
Reiterated: Buy
Price Target: $361 → $62
Current: $52.74
Upside: +17.56%
Immunocore Holdings
Oct 28, 2026
Reiterated: Buy
Price Target: n/a
Current: $28.40
Upside: -
ABIVAX Société Anonyme
Oct 13, 2026
Reiterated: Buy
Price Target: €132.00 → €131.00
Current: €74.80
Upside: +75.13%
Philogen S.p.A.
Oct 2, 2026
Reiterated: Hold
Price Target: €18.00 → €21.00
Current: €20.95
Upside: +0.24%
ABIVAX Société Anonyme
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $155
Current: $84.18
Upside: +84.14%
Immatics
Aug 18, 2026
Reiterated: Buy
Price Target: $12 → $12
Current: $6.18
Upside: +90.94%
Autolus Therapeutics
Aug 11, 2026
Rated: Buy
Price Target: $5.7 → $5.8
Current: $1.26
Upside: +360.32%
Valneva SE
Apr 22, 2026
Downgraded: Sell
Price Target: $7.5 → $4.9
Current: $5.64
Upside: -13.12%
Apr 9, 2026
Reiterated: Sell
Price Target: $7.25 → $5.81
Current: $9.80
Upside: -40.71%
Apr 9, 2026
Rated: Sell
Price Target: €1.30 → €1.01
Current: €1.72
Upside: -41.11%
Feb 26, 2026
Reiterated: Buy
Price Target: $813 → $910
Current: $894.77
Upside: +1.70%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.7884
Upside: -
Jan 9, 2026
Rated: Hold
Price Target: n/a
Current: $1.24
Upside: -
Jul 30, 2025
Reiterated: Buy
Price Target: $35 → $45
Current: $88.34
Upside: n/a
Mar 21, 2025
Reiterated: Hold
Price Target: €2.85 → €3.30
Current: €2.47
Upside: n/a
Oct 3, 2024
Reiterated: Hold
Price Target: n/a
Current: $122.96
Upside: n/a
Jul 30, 2024
Reiterated: Hold
Price Target: CHF 2.00
Current: CHF 4.04
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $130.34
Upside: n/a
May 30, 2024
Initiated Coverage: Hold
Price Target: $47
Current: $50.41
Upside: n/a
Dec 20, 2023
Reiterated: Buy
Price Target: n/a
Current: $36.62
Upside: n/a
Feb 13, 2023
Reiterated: Hold
Price Target: €90.00 → €100.00
Current: €154.80
Upside: n/a
May 16, 2022
Reiterated: Hold
Price Target: €44.00
Current: €53.00
Upside: n/a
May 4, 2022
Downgraded: Hold
Price Target: $40 → $20
Current: $14.20
Upside: n/a